Wesana Health Holdings Inc
CNSX:WESA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (5.1), the stock would be worth CA$-3.98 (8 057% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.1 | CA$0.05 |
0%
|
| Industry Average | 5.1 | CA$-3.98 |
-8 057%
|
| Country Average | 10.2 | CA$-7.93 |
-15 952%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
W
|
Wesana Health Holdings Inc
CNSX:WESA
|
1m CAD | -0.1 | -0 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
308.8B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 3 417.4 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
102.4B ZAR | 14.3 | 10.6 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
68.5B USD | -18 116.9 | 38 690 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
55.3B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
37.6B CHF | 0 | 0 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.8B USD | -4 348.4 | -3 284.6 | |
| US |
|
Coupang Inc
F:788
|
31.5B EUR | 31.9 | 174.3 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
30.1B ZAR | 17.6 | 6.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7 |
| Median | 10.2 |
| 70th Percentile | 14.5 |
| Max | 13 731.1 |
Other Multiples
Wesana Health Holdings Inc
Glance View
Wesana Health Holdings, Inc. engages in development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury. The company is headquartered in Toronto, Ontario. The company went IPO on 2011-12-13. The firm is engaged in development and delivery of psychedelic and naturally sourced therapies to treat traumatic brain Injury related depressive disorder, anxiety and migraines through drug development and predictive diagnostics. The firm is also engaged in care development through its therapies and patent-pending protocols, and in care delivery through activating a multidisciplinary, technology-supported clinical model. Its SANA-013 is a novel composition and method of use that provides sustained effects and benefit over time. The Company’s novel and proprietary depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen of a micro dose of psilocybin combined with cannabidiol, significantly reduced depressive behaviors in a validated animal model.
